Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT05452928
PHASE4

Aciclovir Versus Placebo for HSV-2 Meningitis

Sponsor: Jacob Bodilsen

View on ClinicalTrials.gov

Summary

To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation

Official title: Aciclovir for HSV-2 Meningitis: A Double-blind Randomised Controlled Trial (AMEN)

Key Details

Gender

All

Age Range

Any - Any

Study Type

INTERVENTIONAL

Enrollment

150

Start Date

2026-06-01

Completion Date

2029-06-01

Last Updated

2025-10-01

Healthy Volunteers

Yes

Interventions

DRUG

Acyclovir 50 MG/ML

Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.

DRUG

Placebo

Placebo either in IV formulation or as tablets identical to valacyclovir tablets.